Welcome to our dedicated page for Bellus Health news (Ticker: BLU), a resource for investors and traders seeking the latest updates and insights on Bellus Health stock.
Bellus Health Inc. (NASDAQ: BLU) was acquired by GSK in June 2023 for $2.0 billion. Prior to the acquisition, news coverage focused on the company's development of camlipixant (BLU-5937), a selective P2X3 antagonist for refractory chronic cough treatment.
Historical news about Bellus Health covered clinical trial results, regulatory milestones, and partnership announcements. The company's Phase 2b SOOTHE trial results in December 2021 generated significant media attention, as the data demonstrated a 34% reduction in cough frequency with only 6.5% of patients experiencing taste-related adverse events, substantially lower than competing therapies.
Acquisition-related news in 2023 highlighted GSK's strategic entry into the chronic cough treatment market and the premium valuation paid for access to camlipixant. Following the acquisition, news about the asset's development now appears under GSK's corporate umbrella, with updates focusing on Phase 3 trial progress and anticipated commercialization timelines.
Since Bellus Health no longer operates as an independent entity, investors and stakeholders following developments related to camlipixant and chronic cough therapeutics should monitor GSK news channels for updates on the drug's progress through late-stage clinical development and regulatory review processes.
BELLUS Health, a clinical-stage biopharmaceutical company focused on novel therapeutics for refractory chronic cough (RCC), announced CEO Roberto Bellini's participation in two healthcare investor conferences. The events are the Jefferies 2022 London Healthcare Conference on November 16 at 3:00 a.m. EST and the Evercore ISI HealthCONx Conference on November 30 at 2:15 p.m. EST. BELLUS Health is preparing to initiate its CALM Phase 3 program for its product candidate, BLU-5937, after successful Phase 2b trials.
BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) announced that an abstract from the Phase 2b SOOTHE trial will be presented at the CHEST Annual Meeting from October 16-19, 2022. The presentation details prior consultations and treatments in patients with refractory chronic cough (RCC). The company's product BLU-5937, aimed at RCC, has completed Phase 2b trials and is preparing for the CALM Phase 3 program in Q4 2022. RCC affects about 9 million patients in the U.S., with significant quality of life impacts and limited treatment options available.
BELLUS Health Inc. (NASDAQ:BLU) announced that CEO Roberto Bellini will present a corporate overview at the H.C. Wainwright 24th Annual Global Investment Conference on September 12, 2022, at 7:00 a.m. ET. This presentation will include an update on the Company's pipeline, particularly the Phase 2b trial results of its product candidate, BLU-5937, aimed at treating refractory chronic cough (RCC). Following the event, a recorded webcast will be available on the Company's website, which is focused on developing innovative therapies for cough hypersensitivity indications.
BELLUS Health has announced the presentation of three abstracts from the Phase 2b SOOTHE trial at the European Respiratory Society International Congress 2022 in Barcelona, Spain, on September 4. The abstracts focus on participant characteristics, efficacy, and improvements in cough frequency with BLU-5937, a potential treatment for refractory chronic cough (RCC). The company plans to initiate the CALM Phase 3 program for BLU-5937 in Q4 2022. Currently, no specific therapies are approved for RCC in the US, highlighting a significant unmet medical need.
BELLUS Health Inc. (NASDAQ:BLU) announced positive outcomes from its End-of-Phase 2 meeting with the FDA and received scientific advice from the EMA for its CALM Phase 3 program, targeting refractory chronic cough (RCC) with its candidate, BLU-5937. The company ended Q2 2022 with pro-forma cash of approximately US$384.6 million, extending its cash runway to 2025. They completed a successful US$176 million public offering and plan to initiate pivotal trials CALM-1 and CALM-2 in Q4 2022, with topline results expected in 2024.
BELLUS Health has completed its underwritten public offering of 16,540,541 common shares at US$9.25 each, generating US$153 million in gross proceeds. The company plans to use the net proceeds to fund research and development activities for its product candidate, BLU-5937, alongside working capital and general corporate needs. The offering included a 30-day option for underwriters to purchase an additional 2,481,081 shares. The company’s shares are dual-listed on Nasdaq and the Toronto Stock Exchange under the symbol BLU.
BELLUS Health announced a public offering of 16,540,541 common shares priced at
BELLUS Health has filed a preliminary prospectus supplement for a proposed public offering of its common shares. This follows the amended and restated short form base shelf prospectus dated December 14, 2021. The offering aims to generate funds primarily for research and development of its product candidate, BLU-5937, along with other corporate needs. The underwriters may purchase up to an additional 15% of common shares. The offering will depend on market conditions and regulatory approvals from the Toronto Stock Exchange.
BELLUS Health announced a successful End-of-Phase 2 meeting with the FDA regarding its investigational product BLU-5937 for refractory chronic cough (RCC). The CALM Phase 3 program will feature two pivotal trials, CALM-1 and CALM-2, aiming to enroll around 675 adults. Key endpoints include assessing 24-hour cough frequency at 12 and 24 weeks. The first patient is expected to be enrolled in Q4 2022, with topline results from CALM-1 anticipated in 2H 2024. This represents a crucial step towards potential approval for BLU-5937, positioned as a leading treatment option for RCC.
BELLUS Health Inc. (Nasdaq:BLU) announced that CEO Roberto Bellini will participate in a fireside chat at the William Blair Biotech Focus Conference on July 11, 2022, at 9:00 a.m. ET. The chat will be prerecorded, and a webcast will be available on the company’s website afterward. BELLUS Health is focused on developing therapeutics for refractory chronic cough (RCC), a condition affecting around 9 million patients in the U.S. The company's candidate, BLU-5937, has completed Phase 2b trials and a Phase 3 program is expected to commence in the second half of 2022.
FAQ
What is the market cap of Bellus Health (BLU)?
